Head Lice -

Louse Home Remedies   -

Suggested remedies for Head Lice

Drown the  lice by covering your skin in olive oil for several hours.

Head Lice Remedies

For head lice problems rinse your hair with vinegar. Vinegar  helps in killing all the lice nits in a matter of days.

Coconut oil for massaging hair scalp after helps.

For head lice use Listerine (original flavor): Another remedy for treating head lice is rubbing listerine mouth wash on your head. This will kill all the lice.

Massage your head with mayonnaise and comb it after 2 hours. This will kill all the lice and their eggs. Apply a mixture of lemon and butter on your head, wait for 15 seconds and then rinse your head.

An anti-lice oil can be mixed with coconut (or mustard) oil and 0.2 per cent lindane (BHC) or 0.1 per cent pyrethrum essence. This oil can be rubbed well into the scalp to kill lice. (Ingredients can be purchased from a chemical dealer).

Mix talcum powder with 0.2 per cent prethrum dust in it (or add 10 per cent DDT). Sprinkle this powder on the hair before going to bed and rub it vigorously so that it reaches the roots. Cover your mouth, nose and eyes to protect them from the powder.

Anti-louse lotion, either gammabenzene hexachloride lotion or cream (Lorexane, Gammaexane) or Malathion (Prioderma) will kill the eggs which can be removed by a comb with very fine teeth. One treatment is enough but all the family who are infested should be treated and the hair examined regularly for a while. You may consult a doctor for the treatment.

To remove head lice and their nits. put any common lotion on your  skin generously and then comb your hair out with a regular comb to get any knots out then comb out with a fine tooth comb.

Some people swear by using a common cheap hair gel put on generously & left on under a shower cap for several hours or overnight to smother the bugs etc

Sourced & published by Henry Sapiecha

WHY? Because even though milk may seem soothing at first, it makes your body secrete gastrin — a hormone that encourages the release of MORE ACID!

Smarter remedy. Cabbage juice! This homegrown cure turns out to be real because it’s incredibly rich in the natural compounds glutamine and gefarnate. These substances are so good at rebuilding your stomach lining, one of them is now the basis of an antiulcer drug!

Sourced & published by Henry Sapiecha

HEALTH WARNING:

Soap and water will NOT remove poisonous pesticides from your produce. You can do something far more effective.

Just mix lemon juice, salt and cold water,

This simple rinse creates a diluted form of hydrochloric acid, removing sprays without scrubbing!

Sourced & published by Henry Sapiecha

Biologists Develop Machine

To Remove Viruses From Blood

June 1, 2008 — Infectious disease experts designed a machine called the hemopurifier. It works much like a dialysis machine, using thin fibers to capture and remove viruses from the blood it filters. The machine requires the drawing of blood through an artery, which is sent through a tube into the machine, then back into the body. It can treat a number of illnesses.

Every day, 14,000 people are infected with HIV, the virus that leads to AIDs. There’s no cure, but now a breakthrough — a machine that could clean blood, keeping more and more people alive longer.

“I remember lying in bed thinking, ‘I am going to die. I’m going to die. I feel so sick.’ And I remember thinking laying in that bed, ‘And I know exactly what it is,’” HIV patient John Paul Womble, told Ivanhoe. HIV could kill Womble. He watched his father die from the virus and now he is living the rest of his life with it. “I’ve got to live as healthy as I can, but this virus is not going to control me,” he says. Now, a machine could help clean Womble’s infected blood and keep him healthier, longer.

“It’s designed to mimic the natural immune response of clearing viruses and toxins before cells and organs can be infected,” Jim Joyce chairman and CEO of Aethlon Medical in San Diego, told Ivanhoe. Developed by infectious disease and biodefense experts, the hemopurifier works like a dialysis machine. Antibodies on these spaghetti-like fibers capture and remove viruses as blood filters through it.

“Your entire circulation flows through the cartridge about once every eight minutes,” Joyce explains. The entire process takes less than a few hours. It could help patients infected with HIV, hepatitis C, as well as people with the measles, mumps and the flu. “The cartridge is able to selectively capture viruses.”

A larger version of the machine would be used in a hospital, but a smaller one could be taken to emergencies. It could be a life-safer against the avian flu or bio-weapons like Ebola and small pox, giving people a chance to survive a deadly attack, whether it’s from a terrorist or a virus.

“I don’t have to be afraid,” Womble says. “I have a virus. I’ve got to do something about that virus. I’ve got to treat that virus. I’ve got to live as healthy as I can.” The hemopurifier is also a leading treatment candidate to protect United States civilian and military populations from bioterror threats and emerging pandemic threats like the bird flu and dengue fever that are untreatable with drugs and vaccines.

Appears to Keep Cancer in Check

in Majority of CLL Patients

Science (June 4, 2010) — An extract of green tea appears to have clinical activity with low toxicity in chronic lymphocytic leukemia (CLL) patients who used it in a phase II clinical trial, say researchers at Mayo Clinic.

The findings were presented June 7 during the annual meeting of the American Society of Clinical Oncology (ASCO). They are the latest in a series of Mayo studies to show promise for use of the chemical epigallocatechin gallate (EGCG) — the major component of green tea — in reducing the number of leukemia cells in patients with CLL. Mayo first tested EGCG in a variety of laboratory assays about eight years ago, and it was found to reduce the survival of CLL leukemic cells. This laboratory finding was followed by a successful phase I clinical trial — the first time green tea extract had been studied in CLL patients.

“Although only a comparative phase III trial can determine whether EGCG can delay progression of CLL, the benefits we have seen in most CLL patients who use the chemical suggest that it has modest clinical activity and may be useful for stabilizing this form of leukemia, potentially slowing it down,” says Tait Shanafelt, M.D., a Mayo Clinic hematologist and lead author of the study.

“These studies advance the notion that a nutraceutical like EGCG can and should be studied as cancer preventives,” says Neil Kay, M.D., a hematology researcher whose laboratory first tested the green tea extract in leukemic blood cells from CLL patients. “Using nontoxic chemicals to push back cancer growth to delay the need for toxic therapies is a worthy goal in oncology research — particularly for forms of cancer initially managed by observation such as CLL.”

Drs. Shanafelt and Kay caution that EGCG is not a substitute for chemotherapy. All of the patients Mayo tested with EGCG were early stage, asymptomatic CLL patients who would not otherwise be treated until their disease progressed. The extract was supplied by the National Cancer Institute (NCI) and Polyphenon E International for these initial clinical trials.

CLL is a blood cancer that is a hybrid between leukemia and lymphoma. Progression of the disease is measured by the quantity of leukemia cells in the blood and bone marrow as well as enlargement of lymph nodes due to infiltration by the leukemia cells. In the phase I study, published in May 2009 in the Journal of Clinical Oncology, researchers found that the blood lymphocyte (leukemia cell) count was reduced in one-third of participants, and that the majority of patients who entered the study with enlarged lymph nodes due to involvement by CLL saw a 50 percent or greater reduction in their lymph node size.

Using the highest dose tested in the phase I study, the researchers launched their phase II clinical trial in an additional 36 patients. The results presented at the ASCO meeting evaluate the effects in these 36 patients as well as the six patients from the phase I trial treated at the same dose (total 42 patients). Results from 41 patients who have completed the study show that 31 percent of patients had a 20 percent or greater sustained reduction in blood leukemia count, and 69 percent of patients with enlarged lymph nodes saw a reduction of node size of 50 percent or greater.

In all, 69 percent of CLL patients had a biological response to EGCG as evidenced by a 20 percent or greater sustained reduction in blood lymphocyte count and/or a 50 percent or greater reduction in lymph node size, the researchers say.

Because EGCG was being studied in patients who did not otherwise need treatment, the researchers took a rigorous approach toward studying side effects. Most clinical trials of therapeutic agents only report grade 3 and higher side effects, but the researchers looked at and reported grade 1 and grade 2 as well. While a number of patients had transient grade 1 or 2 side effects, only three of 42 experienced a grade 3 side effect during their six months of treatment.

“All in all, the treatment was well tolerated with very mild side effects in most patients,” Dr. Shanafelt says.

The researchers say that the prior publications on the effects of EGCG on CLL leukemia cells in the laboratory and the data from the published phase I study have been widely disseminated via the Internet by patient advocacy groups. Based on information from patients and colleagues throughout the country, the Mayo researchers have become aware that many CLL patients nationwide have started to use EGCG supplements, which are readily available over the counter.

“Without a phase III clinical trial, we cannot make a recommendation that EGCG be used by CLL patients, but those who want to take supplements should consult with their oncologists and need to receive appropriate monitoring using laboratory tests,” Dr. Kay says.

The study was funded by grants from the NCI, the Mayo Comprehensive Cancer Center and from donors and patient advocacy foundations.

Sourced & published by Henry Sapiecha

by maggots

A combination of nanotechnology and adult stem cells has been shown to destroy arterial plaque atherosclerosis in the hearts of pigs. Animals that received stem cells also showed signs of new blood vessel growth and restoration of artery function, according to the study reported at the American Heart Association’s Basic Cardiovascular Sciences 2010 Scientific Sessions.

The study was conducted at the Department of Internal Medicine and Research Center of Regenerative Medicine, Ural State Medical Academy in Yekaterinburg, Russia. Nanoparticles were infused into the heart of pigs, along with adult stem cells, then heated by laser light until they burned away arterial plaque. The volume of plaque shrunk an average of 28.9 percent immediately after treatment across the three treatment groups, and six months later it had declined 56.8 percent on average. In the control group, plaque volume increased an average of 4.3 percent.

“Biophotonics (light therapy), plasmonics (plasma therapy), stem cell therapy and nanotechnology might someday offer a completely novel treatment to reduce artery plaque build-up,” said lead author and research manager Alexandr Kharlamov. “Nanoburning in combination with stem cell treatment promises demolition of plaque and functional restoration of the vessel wall.”

This new approach may one day replace angioplasty, a common treatment for atherosclerosis, in which a balloon-tipped catheter is threaded into a blocked artery and the balloon is inflated to restore blood flow. The balloon squeezes plaque against the artery wall, but does not eliminate it.

Sourced & published by Henry Sapiecha